O	0	4	Full	Full	JJ	B-NP
O	5	15	sequencing	sequencing	NN	I-NP
O	16	24	analysis	analysis	NN	I-NP
O	25	27	of	of	IN	B-PP
O	28	36	estrogen	estrogen	NN	B-NP
O	37	45	receptor	receptor	NN	I-NP
O	45	46	-	-	HYPH	B-NP
O	46	51	alpha	alpha	SYM	I-NP
O	52	56	gene	gene	NN	I-NP
O	57	69	polymorphism	polymorphism	NN	I-NP
O	70	73	and	and	CC	O
O	74	77	its	its	PRP$	B-NP
O	78	89	association	association	NN	I-NP
O	90	94	with	with	IN	B-PP
B-Cancer	95	101	breast	breast	NN	B-NP
I-Cancer	102	108	cancer	cancer	NN	I-NP
O	109	113	risk	risk	NN	I-NP
O	113	114	.	.	.	O

O	115	125	BACKGROUND	BACKGROUND	NN	B-NP
O	125	126	:	:	:	O

O	127	130	The	The	DT	B-NP
O	131	139	estrogen	estrogen	NN	I-NP
O	140	148	receptor	receptor	NN	I-NP
O	149	154	plays	play	VBZ	B-VP
O	155	156	a	a	DT	B-NP
O	157	165	critical	critical	JJ	I-NP
O	166	170	role	role	NN	I-NP
O	171	173	in	in	IN	B-PP
B-Cancer	174	180	breast	breast	NN	B-NP
I-Cancer	181	187	cancer	cancer	NN	I-NP
O	188	199	development	development	NN	I-NP
O	200	203	and	and	CC	O
O	204	215	progression	progression	NN	B-NP
O	215	216	.	.	.	O

O	217	219	So	So	IN	O
O	220	223	the	the	DT	B-NP
O	224	231	genetic	genetic	JJ	I-NP
O	232	244	polymorphism	polymorphism	NN	I-NP
O	245	247	of	of	IN	B-PP
O	248	250	ER	ER	NN	B-NP
O	250	251	-	-	HYPH	O
O	251	256	alpha	alpha	SYM	O
O	257	261	gene	gene	NN	B-NP
O	262	267	could	could	MD	B-VP
O	268	274	affect	affect	VB	I-VP
B-Cancer	275	281	cancer	cancer	NN	B-NP
O	282	286	risk	risk	NN	I-NP
O	287	290	and	and	CC	I-NP
O	291	300	phenotype	phenotype	NN	I-NP
O	300	301	.	.	.	O

O	302	311	MATERIALS	MATERIALS	NNS	B-NP
O	312	315	AND	AND	CC	I-NP
O	316	323	METHODS	METHODS	NNS	I-NP
O	323	324	:	:	:	O

O	325	327	We	We	PRP	B-NP
O	328	333	fully	fully	RB	B-ADVP
O	334	343	sequenced	sequence	VBD	B-VP
O	344	347	the	the	DT	B-NP
O	348	350	ER	ER	NN	I-NP
O	350	351	-	-	HYPH	O
O	351	356	alpha	alpha	SYM	O
O	357	361	gene	gene	NN	B-NP
O	362	364	to	to	TO	B-VP
O	365	376	investigate	investigate	VB	I-VP
O	377	380	its	its	PRP$	B-NP
O	381	387	single	single	JJ	I-NP
O	388	398	nucleotide	nucleotide	NN	I-NP
O	399	412	polymorphisms	polymorphism	NNS	I-NP
O	413	414	(	(	(	O
O	414	418	SNPs	SNP	NNS	B-NP
O	418	419	)	)	)	O
O	420	422	in	in	IN	B-PP
O	423	426	100	100	CD	B-NP
B-Cancer	427	433	breast	breast	NN	I-NP
I-Cancer	434	440	cancer	cancer	NN	I-NP
O	441	449	patients	patient	NNS	I-NP
O	450	453	and	and	CC	O
O	454	457	100	100	CD	B-NP
O	458	466	controls	control	NNS	I-NP
O	466	467	.	.	.	O

O	468	475	RESULTS	RESULTS	NNS	B-NP
O	475	476	:	:	:	O

O	477	480	Six	Six	CD	B-NP
O	481	486	novel	novel	JJ	I-NP
O	487	499	polymorphism	polymorphism	NN	I-NP
O	500	502	in	in	IN	B-PP
O	503	506	the	the	DT	B-NP
O	507	514	control	control	NN	I-NP
O	515	518	and	and	CC	O
O	519	521	11	11	CD	B-NP
O	522	524	in	in	IN	B-PP
B-Cancer	525	531	cancer	cancer	NN	B-NP
O	532	540	patients	patient	NNS	I-NP
O	541	545	were	be	VBD	B-VP
O	546	551	found	find	VBN	I-VP
O	551	552	.	.	.	O

O	553	556	The	The	DT	B-NP
O	557	558	G	G	NN	I-NP
O	558	559	/	/	SYM	B-VP
O	559	560	G	G	NN	B-NP
O	561	569	genotype	genotype	NN	I-NP
O	570	572	at	at	IN	B-PP
O	573	577	C975	C975	NN	B-NP
O	578	579	G	G	NN	I-NP
O	580	583	and	and	CC	I-NP
O	584	585	A	A	NN	I-NP
O	585	586	/	/	SYM	I-NP
O	586	587	A	A	NN	I-NP
O	588	596	genotype	genotype	NN	I-NP
O	597	599	at	at	IN	B-PP
O	600	605	G1782	G1782	NN	B-NP
O	606	607	A	A	NN	I-NP
O	608	611	had	have	VBD	B-VP
O	612	613	a	a	DT	B-NP
O	614	624	protective	protective	JJ	I-NP
O	625	631	effect	effect	NN	I-NP
O	632	639	against	against	IN	B-PP
B-Cancer	640	646	breast	breast	NN	B-NP
I-Cancer	647	653	cancer	cancer	NN	I-NP
O	654	658	when	when	WRB	B-ADVP
O	659	667	compared	compare	VBN	B-VP
O	668	670	to	to	TO	B-PP
O	671	676	other	other	JJ	B-NP
O	677	686	genotypes	genotype	NNS	I-NP
O	687	688	(	(	(	O
O	688	690	OR	OR	NN	B-NP
O	691	692	=	=	SYM	B-VP
O	693	694	0	0	CD	B-NP
O	694	695	.	.	SYM	I-NP
O	695	696	3	3	CD	I-NP
O	697	700	and	and	CC	I-NP
O	701	702	0	0	CD	I-NP
O	702	703	.	.	.	I-NP
O	703	704	3	3	CD	I-NP
O	704	705	,	,	,	O
O	706	718	respectively	respectively	RB	B-ADVP
O	718	719	)	)	)	O
O	719	720	.	.	.	O

O	721	725	975G	975G	NN	B-NP
O	726	732	allele	allele	NN	I-NP
O	733	736	was	be	VBD	B-VP
O	737	747	associated	associate	VBN	I-VP
O	748	757	inversely	inversely	RB	B-ADVP
O	758	762	with	with	IN	B-PP
O	763	766	the	the	DT	B-NP
O	767	770	p53	p53	NN	I-NP
O	771	781	expression	expression	NN	I-NP
O	782	785	and	and	CC	O
O	786	796	positively	positively	RB	B-ADVP
O	797	801	with	with	IN	B-PP
O	802	805	the	the	DT	B-NP
O	806	809	bcl	bcl	NN	I-NP
O	809	810	-	-	HYPH	O
O	810	811	2	2	CD	B-NP
O	812	822	expression	expression	NN	I-NP
O	823	825	in	in	IN	B-PP
B-Cancer	826	832	cancer	cancer	NN	B-NP
O	833	837	with	with	IN	B-PP
O	838	848	borderline	borderline	JJ	B-NP
O	849	861	significance	significance	NN	I-NP
O	861	862	.	.	.	O

O	863	872	Combining	Combine	VBG	B-VP
O	873	877	this	this	DT	B-NP
O	878	884	result	result	NN	I-NP
O	885	889	with	with	IN	B-PP
O	890	893	our	our	PRP$	B-NP
O	894	902	previous	previous	JJ	I-NP
O	903	908	study	study	NN	I-NP
O	908	909	,	,	,	O
O	910	915	these	these	DT	B-NP
O	916	928	associations	association	NNS	I-NP
O	929	935	became	become	VBD	B-VP
O	936	940	more	more	RBR	B-ADJP
O	941	952	significant	significant	JJ	I-ADJP
O	953	954	(	(	(	O
O	954	955	p	p	NN	B-NP
O	956	957	=	=	SYM	B-VP
O	958	959	0	0	CD	B-NP
O	959	960	.	.	SYM	I-NP
O	960	963	005	005	CD	I-NP
O	964	967	and	and	CC	I-NP
O	968	969	0	0	CD	I-NP
O	969	970	.	.	.	I-NP
O	970	973	019	019	CD	I-NP
O	973	974	,	,	,	O
O	975	987	respectively	respectively	RB	B-ADVP
O	987	988	)	)	)	O
O	988	989	.	.	.	O

O	990	1000	CONCLUSION	CONCLUSION	NN	B-NP
O	1000	1001	:	:	:	O

O	1002	1015	Polymorphisms	Polymorphism	NNS	B-NP
O	1016	1018	in	in	IN	B-PP
O	1019	1021	ER	ER	NN	B-NP
O	1021	1022	-	-	HYPH	O
O	1022	1027	alpha	alpha	SYM	O
O	1028	1032	gene	gene	NN	B-NP
O	1033	1036	can	can	MD	B-VP
O	1037	1043	affect	affect	VB	I-VP
O	1044	1047	the	the	DT	B-NP
B-Cancer	1048	1054	breast	breast	NN	I-NP
I-Cancer	1055	1061	cancer	cancer	NN	I-NP
O	1062	1076	susceptibility	susceptibility	NN	I-NP
O	1077	1080	and	and	CC	O
O	1081	1084	may	may	MD	B-VP
O	1085	1087	be	be	VB	I-VP
O	1088	1095	related	related	JJ	B-ADJP
O	1096	1098	to	to	TO	B-PP
O	1099	1104	other	other	JJ	B-NP
O	1105	1112	protein	protein	NN	I-NP
O	1113	1123	expression	expression	NN	I-NP
O	1123	1124	,	,	,	O
O	1125	1129	such	such	JJ	B-PP
O	1130	1132	as	as	IN	I-PP
O	1133	1136	p53	p53	NN	B-NP
O	1137	1140	and	and	CC	I-NP
O	1141	1144	bcl	bcl	NN	I-NP
O	1144	1145	-	-	HYPH	B-NP
O	1145	1146	2	2	CD	I-NP
O	1146	1147	.	.	.	O

